Table 6.
Response to therapy evaluation guided RAT through guidelines.
| ATA guidelines | NCCN guidelines |
2018CSCO guidelines | ||||
|---|---|---|---|---|---|---|
| Indications | 2009 ATA guidelines | 2015 ATA guidelines | 2018 NCCN guidelines | 2020 NCCN guidelines | 2021 NCCN guidelines | |
| Response-to-therapy evaluation guided | NS | Tg levels↑ | NS | NS | NS | Tg(+)WBS(-) or Tg(+)18F FDG PET/CT(-) (ps-Tg≥10 ng/ml) |
| Dosage | 100-200 mCi | 30-150 mCi | 50-100 mCi | 50-200 mCi | 50-100mCi | 100-200mCi |
| T3&N1: the effectiveness of RAT >150 mCi is uncertain | RAI for known disease (100-200mCi) is embodied in RAT (50-100mCi). | >150mCi should be avoided in patients≥70y | ||||
WBS, whole-body scan, especially 131I-diagnostic whole-body scan, also as Dx-WBS; ps-Tg, post-operative stimulated Tg; FDG PET/CT, fluorodeoxyglucose positron emission tomography; NS, not stated.